ReviewResearch (Washington, D.C.)2025
Microbial Interactions with Intestinal Lipid Digestion and Absorption: Emerging Targets for Metabolic Disorders.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Research Progress on the Regulatory Mechanisms of Gut Microbiota in Methamphetamine Addiction and Targeted Interventions.Addiction biology · 2026Review
- Choline counteracts pregnancy undernutrition-associated colitis in sheep by restoring microbiota driven bile acid metabolism.NPJ biofilms and microbiomes · 2026Article
- Gut Microbiota-Derived Short-Chain Fatty Acids in Inflammatory Bowel Disease: Mechanistic Insights into Gut Inflammation, Barrier Function, and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Gut microbiota-immune crosstalk in childhood and adolescent obesity: mechanistic insights and therapeutic potential focused on short-chain fatty acids and emerging metabolites.Frontiers in microbiology · 2026Review
- Dose-response relationships of normal blood lipid levels in metabolic and endocrine diseases: mechanistic similarities, differences, and functional insights.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dietary fat undergoes digestion and absorption before entering enterocytes, where lipids are re-esterified and packaged into chylomicrons for lymphatic transport. The interaction between intestinal lipid absorption and metabolic disorders, such as obesity, has been demonstrated in both animal models and human studies. Here, we comprehensively review microbial interactions with intestinal lipase secretion and lipid absorption as well as the potential mechanisms associated with microbial metabolites, bile acids, immune cells, Snhg9, toll-like receptors, and intestinal permeability. We also highlight the relevance of these findings to metabolic diseases and their potential application in developing therapies that target intestinal lipid absorption through the modulation of gut microbiota, such as the use of probiotics and dietary nutrients. Finally, key questions regarding microbial interactions with intestinal lipid absorption are outlined to guide future research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.